title: Interpreting outcome data in hematological malignancies: a paradigm for clinical studies.
abstract: Results of clinical studies are often contradictory in real time, and in other instances therapies may be adopted due to information from clinical studies where the data may be premature or resulting from small studies. Much of the data may have inherent selection biases, and their interpretation may be confusing and difficult. The hematological literature is full of such examples, and this review will describe some such instances in the hope of introducing both a cautionary note and encouraging more precise description of study conditions as well as an appreciation of the importance of allowing data from clinical studies to mature. Several examples will be drawn from clinical studies in lymphomas, leukemia, and bone marrow transplantation.
authors.affiliation: Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel; Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel; and Technion, Israel Institute of Technology, Haifa, Israel.
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Rowe
keywords: Bone marrow transplantation; hematological malignancies; leukemia; lymphoma; outcome data
references.citation: Cancer. 1976 Oct;38(4):1484-93
references.pmid: 791473
references.citation: Cancer Treat Rep. 1977 Oct;61(7):1307-17
references.pmid: 589597
references.citation: N Engl J Med. 1995 Dec 7;333(23):1540-5
references.pmid: 7477169
references.citation: Blood. 1987 Feb;69(2):388-93
references.pmid: 3542078
references.citation: J Clin Oncol. 2004 Oct 15;22(20):4075-86
references.pmid: 15353542
references.citation: N Engl J Med. 2009 Sep 24;361(13):1249-59
references.pmid: 19776406
references.citation: Blood. 2008 Feb 15;111(4):1827-33
references.pmid: 18048644
references.citation: Blood. 1990 Feb 1;75(3):555-62
references.pmid: 2297567
references.citation: Blood. 2007 Apr 15;109(8):3189-97
references.pmid: 17170120
references.citation: Blood. 1985 Sep;66(3):664-72
references.pmid: 3896348
references.citation: Blood. 2007 Feb 1;109(3):944-50
references.pmid: 17032921
references.citation: Ann Intern Med. 1988 Jun;108(6):806-14
references.pmid: 3285744
references.citation: Blood. 2013 Feb 14;121(7):1077-82
references.pmid: 23243288
references.citation: J Clin Oncol. 2009 Jan 1;27(1):61-9
references.pmid: 19047294
references.citation: Cancer Treat Rep. 1982 Mar;66(3):439-49
references.pmid: 7060033
references.citation: Blood. 2005 May 1;105(9):3420-7
references.pmid: 15572587
references.citation: Nat Rev Clin Oncol. 2012 Oct;9(10):579-90
references.pmid: 22949046
references.citation: J Clin Oncol. 2011 Feb 1;29(4):369-77
references.pmid: 21172891
references.citation: Blood. 1991 Oct 15;78(8):2120-30
references.pmid: 1912589
references.citation: N Engl J Med. 1998 Dec 3;339(23):1649-56
references.pmid: 9834301
references.citation: N Engl J Med. 1995 Jun 22;332(25):1671-7
references.pmid: 7760868
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: Ann Intern Med. 1985 Jul;103(1):140-2
references.pmid: 2408529
references.citation: N Engl J Med. 1993 Apr 8;328(14):1002-6
references.pmid: 7680764
references.citation: Best Pract Res Clin Haematol. 2012 Dec;25(4):403-8
references.pmid: 23200535